Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Recruiting now · Phase 1/Phase 2
Conditions studied: Metastatic Prostate Cancer
In brief
Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Key facts
- Study ID
- NCT06800313
- Run by
- Janssen Research & Development, LLC
- People needed
- 190
- Starts
- 2025-02-20
- Expected to finish
- 2030-04-01
- Last updated by the study team
- 2026-06-26
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States (enrolling)
- Yale - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut, United States (enrolling)
- Florida Cancer Specialists — Sarasota, Florida, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- START Midwest, LLC — Grand Rapids, Michigan, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Duke University Medical Center — Durham, North Carolina, United States (enrolling)
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- NEXT Austin — Austin, Texas, United States (enrolling)
- The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Royal Marsden Hospital — Sutton, Surrey, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.